• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agency of Health Technology Assessment of Uruguay
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canada’s Drug Agency (CDA-AMC)
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Healthcare Quality Institute
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Regione Emilia Romagna
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply
Sort by Relevance
CSV RIS
Search Results [551 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2026 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [X-ray image of the lung: Can artificial intelligence support the analysis of X-ray images?]
2025 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Serplulimab (small cell lung cancer, first line) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2025 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (small cell lung cancer, non-advanced) – Benefit assessment according to § 35a SGB V]
2025 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (NSCLC, neoadjuvant + adjuvant) – Benefit assessment according to §35a Social Code Book V]
2025 National Institute for Health and Care Excellence (NICE) Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer. NICE technology appraisal guidance 1030
2025 Scottish Health Technologies Group (SHTG) Artificial intelligence-assisted clinician review of chest X-rays for suspected lung cancer
2025 National Institute for Health and Care Excellence (NICE) Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer. NICE technology appraisal guidance 1108
2025 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Proton therapy in cancer treatment: evaluation of safety, efficacy, effectiveness, and efficiency]
2025 National Institute for Health and Care Excellence (NICE) Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 1060
2025 Institut national d'excellence en sante et en services sociaux (INESSS) [Lung cancer treatment algorithm]
2025 National Institute for Health and Care Excellence (NICE) Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection. NICE technology appraisal guidance 1043
2025 National Institute for Health and Care Excellence (NICE) Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer. NICE technology appraisal guidance 1041
2025 National Institute for Health and Care Excellence (NICE) Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 1042
2025 National Institute for Health and Care Excellence (NICE) Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments. NICE technology appraisal guidance 1091
2025 National Institute for Health and Care Excellence (NICE) Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer. NICE technology appraisal guidance 1037
2025 NIHR Health Technology Assessment programme Software with artificial intelligence-derived algorithms for detecting and analysing lung nodules in CT scans: systematic review and economic evaluation
2025 Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Clinical follow-up of incidental pulmonary nodules: progress report on the selection of efficacy and safety indicators]
2025 Institute of Health Economics (IHE) PET/CT capacity for cancer diagnosis and follow-up: rapid review
2025 National Institute for Health and Care Excellence (NICE) Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer. NICE technology appraisal guidance 1071
2025 National Institute for Health and Care Excellence (NICE) Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 1072
2025 Agency for Care Effectiveness (ACE) Pembrolizumab for treating resectable Stage II, IIIA, or IIIB (T3-4N2) non-small-cell lung cancer
2025 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tislelizumab (NSCLC, second line or later) – Addendum to Project A24-128]
2025 National Institute for Health and Care Excellence (NICE) Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (terminated appraisal). NICE technology appraisal guidance 1047
2025 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Osimertinib (locally advanced, unresectable NSCLC) – Benefit assessment according to §35a Social Code Book V]
2025 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Osimertinib (locally advanced, unresectable NSCLC) – Addendum to Project A25-03]
2025 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lazertinib (NSCLC, first line, in combination with amivantamab) – Benefit assessment according to §35a Social Code Book V]
2025 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Amivantamab (NSCLC, pretreated) – Benefit assessment according to §35a Social Code Book V]
2025 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Amivantamab (NSCLC, combination with carboplatin and pemetrexed) – Benefit assessment according to §35a Social Code Book V]
2025 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Osimertinib (NSCLC, combination with pemetrexed and platinum-based chemotherapy) – benefit assessment according to §35a Social Code Book V]
2025 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (NSCLC, perioperative) – Benefit assessment according to §35a Social Code Book V]
2025 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Osimertinib (NSCLC, combination with pemetrexed and platinum-based chemotherapy) – Addendum to Project A24-77]
2025 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tislelizumab (squamous NSCLC, first line) – benefit assessment according to §35a Social Code Book (SGB) V]
2025 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tislelizumab (non-squamous NSCLC) - benefit assessment according to §35a Social Code Book (SGB) V]
2025 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tislelizumab (NSCLC, second line) - benefit assessment according to § 35a Social Code Book (SGB) V]
2025 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC, first line) – addendum to Project A24-97]
2025 National Institute for Health and Care Excellence (NICE) Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor. NICE technology appraisal guidance 1103
2025 National Institute for Health and Care Excellence (NICE) Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy. NICE technology appraisal guidance 1099
2025 Center for Drug Evaluation (CDE) [HTA Rapid report-Tecentriq (Subcutaneous injection)]
2025 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Consumer health information on lung cancer screening using low-dose computed tomography]
2025 Center for Drug Evaluation (CDE) [HTA Rapid report-Keytruda (metastatic non-squamous non-small cell-NSCLC) lung cancer)]
2025 National Institute for Health and Care Excellence (NICE) Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 1058
2025 National Institute for Health and Care Excellence (NICE) Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 1076
2025 Center for Drug Evaluation (CDE) [HTA Rapid report- Tecentriq (NSCLC-first line treatment)]
2025 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (pleural mesothelioma) – Benefit assessment according to §35a Social Code Book V]
2025 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Repotrectinib (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2025 Haute Autorite de sante (HAS) [Next generation sequencing gene panel using circulating tumor DNA for medical lung cancer care]
2024 Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: evaluation of the lung cancer screening pilot project - effects on participants' health and organizational impact on the healthcare system]
2024 Center for Drug Evaluation (CDE) [HTA Rapid report-Yervoy (malignant pleural mesothelioma - MPM)]
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of lung cancer screening using low-dose computed tomography]
2024 Center for Drug Evaluation (CDE) [HTA Rapid report-Lorviqua (ALK+ NSCLC)]
2024 National Institute for Health and Care Excellence (NICE) Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 976
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Binimetinib and encorafenib (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V]
2024 National Institute for Health and Care Excellence (NICE) Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer. NICE technology appraisal guidance 1017
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alectinib (NSCLC, adjuvant) – Addendum to Project A24-73]
2024 Ontario Health Plasma-based comprehensive genomic profiling DNA assays for non-small cell lung cancer
2024 National Institute for Health and Care Excellence (NICE) Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer. NICE technology appraisal guidance 1014
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alectinib (NSCLC, adjuvant) – 2nd Addendum to Project A24-73]
2024 Andalusian Health Technology Assessment Area (AETSA) [Liquid biopsy in lung neoplasms: diagnosis, prognosis and treatment adequacy]
2024 Institut national d'excellence en sante et en services sociaux (INESSS) [Checklist: screening for cancers, chronic diseases and STBBIs]
2024 Belgian Health Care Knowledge Centre (KCE) Lung cancer screening in a high-risk population
2024 Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: initial evaluation of lung cancer patients for whom surgery is the first treatment – portrait of the situation in Québec from 2016 to 2019]
2024 Scottish Health Technologies Group (SHTG) Lung cancer AI
2024 Ontario Health Plasma-based comprehensive genomic profiling DNA assays for non–small cell lung cancer: a health technology assessment
2024 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: diagnostic, prognostic, or predictive multigene panel for non-small cell lung carcinoma (NSCLC) by liquid biopsy (NGS)]
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (NSCLC, neoadjuvant + adjuvant) – Benefit assessment according to § 35a Social Code Book V]
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (NSCLC, adjuvant) – Benefit assessment according to § 35a Social Code Book V]
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (NSCLC, neoadjuvant) – Addendum to Project A23-74]
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Osimertinib (NSCLC, adjuvant) – benefit assessment according to §35a Social Code Book V]
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alectinib (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V]
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (NSCLC, neoadjuvant + adjuvant) – addendum to Project A24-46]
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (NSCLC, neoadjuvant + adjuvant) – Second Addendum to Project A24-46]
2024 NIHR Health and Social Care Delivery Program Artificial intelligence software for analysing chest X-ray images to identify suspected lung cancer: an evidence synthesis early value assessment
2024 National Institute for Health and Care Excellence (NICE) Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 1021
2024 Haute Autorite de sante (HAS) [Next generation sequencing gene panel for medical lung cancer care]
2024 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2023 Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Evaluation of the lung cancer screening program]
2023 Institute for Clinical Effectiveness and Health Policy (IECS) [Nivolumab plus ipilimumab in pleural mesothelioma]
2023 Institute for Clinical Effectiveness and Health Policy (IECS) [Transbronchial biopsy guided by endobronchial ultrasound (EBUS) in pathologies accesible by transbronchial puncture that required anatomopathological diagnosis]
2023 Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Electromagnetic Navigation Bronchoscopy: Use in Dying for Lung Nodules Resection. Horizon Scanning Technologies]
2023 Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Robotic Bronchoscopy for Lung Nodule Diagnostics. Horizon Scanning Technologies]
2023 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tremelimumab and durvalumab (NSCLC) – Second addendum to Project A23-29 | A23-31]
2023 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tremelimumab and durvalumab (NSCLC) - Addendum to Commissions A23-29 and A23-31]
2023 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Computerized clinical decision support systems for decision support in patients with breast, lung, colorectal or prostate cancer]
2023 National Institute for Health and Care Excellence (NICE) Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy. NICE technology appraisal guidance 855
2023 Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Stereotactic virtual navigation systems for percutaneous tumour ablation]
2023 National Institute for Health and Care Excellence (NICE) Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer. NICE technology appraisal guidance 876
2023 National Institute for Health and Care Excellence (NICE) Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal). NICE technology appraisal guidance 884
2023 National Institute for Health and Care Excellence (NICE) AI-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images. NICE diagnostics guidance 55
2023 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sotorasib (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2023 National Institute for Health and Care Excellence (NICE) Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 898
2023 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Endobronchial ultrasonography in malignant and benign pulmonary pathology: linear and radial ultrasound-guided transbronchial needle aspiration: evaluation of safety, efficacy, and cost-effectiveness]
2023 National Institute for Health and Care Excellence (NICE) Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 909
2023 National Institute for Health and Care Excellence (NICE) Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 911
2023 Canary Health Service [Evaluation of the lung cancer screening program]
2023 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tremelimumab (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2023 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2023 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cemiplimab (NSCLC, combination with platin-based chemotherapy) - Benefit assessment according to §35a Social Code Book V]
2023 Health Technology Wales (HTW) Robot-assisted thoracic surgery